62 results on '"Atkins, Helen S."'
Search Results
2. Drug screening to identify compounds to act as co-therapies for the treatment of Burkholderia species
3. Attenuated Bacterial Vaccines
4. Identification and analysis of novel small molecule inhibitors of RNase E: Implications for antibacterial targeting and regulation of RNase E
5. Genome-wide assessment of antimicrobial tolerance in Yersinia pseudotuberculosis under ciprofloxacin stress
6. Drug screening to identify compounds to act as co-therapies for the treatment of pathogenic Burkholderia
7. Disulfiram, an alcohol dependence therapy, can inhibit the in vitro growth of Francisella tularensis
8. A structural and biochemical comparison of Ribonuclease E homologues from pathogenic bacteria highlights species-specific properties
9. The Fluoroquinolone Finafloxacin Protects BALB/c Mice Against an Intranasal Infection With Francisella tularensis Strain SchuS4
10. Global Analysis of Genes Essential for Francisella tularensis Schu S4 Growth In Vitro and for Fitness during Competitive Infection of Fischer 344 Rats
11. High-throughput analysis of Yersinia pseudotuberculosis gene essentiality in optimised in vitro conditions, and implications for the speciation of Yersinia pestis
12. An integrated computational-experimental approach reveals Yersinia pestis genes essential across a narrow or a broad range of environmental conditions
13. Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei
14. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague
15. A Bioluminescent Francisella tularensis SCHU S4 Strain Enables Noninvasive Tracking of Bacterial Dissemination and the Evaluation of Antibiotics in an Inhalational Mouse Model of Tularemia
16. Bacillus anthracis TIR Domain-Containing Protein Localises to Cellular Microtubule Structures and Induces Autophagy
17. Burkholderia pseudomallei kynB plays a role in AQ production, biofilm formation, bacterial swarming and persistence
18. Characterization of New Virulence Factors Involved in the Intracellular Growth and Survival of Burkholderia pseudomallei
19. Establishing an In Vivo Imaging Capability in High-Containment
20. Intracellular replication of the well-armed pathogen Burkholderia pseudomallei
21. The potential of liposome–encapsulated ciprofloxacin as a tularemia therapy
22. Liposome Encapsulation of Ciprofloxacin Improves Protection against Highly Virulent Francisella tularensis Strain Schu S4
23. CpG oligonucleotides protect against Venezuelan equine encephalitis virus infection in a route-dependent manner
24. The ability of CpG oligonucleotides to protect mice against Francisella tularensis live vaccine strain but not fully virulent F. tularensis subspecies holarctica is reflected in cell-based assays
25. Assessment of antimicrobial peptide LL-37 as a post-exposure therapy to protect against respiratory tularemia in mice
26. Galleria mellonella as a model system to test the pharmacokinetics and efficacy of antibiotics against Burkholderia pseudomallei
27. A Toll/interleukin (IL)-1 receptor domain protein from Yersinia pestis interacts with mammalian IL-1/Toll-like receptor pathways but does not play a central role in the virulence of Y. pestis in a mouse model of bubonic plague
28. Design and characterization of novel hybrid antimicrobial peptides based on cecropin A, LL-37 and magainin II
29. Neutrophils are the predominant cell-type to associate with Burkholderia pseudomallei in a BALB/c mouse model of respiratory melioidosis
30. Yersinia pestis TIR-domain protein forms dimers that interact with the human adaptor protein MyD88
31. Potent antimicrobial peptides with selectivity for Bacillus anthracis over human erythrocytes
32. Inhibition ofFrancisella tularensisLVS infection of macrophages results in a reduced inflammatory response: evaluation of a therapeutic strategy for intracellular bacteria
33. Antimicrobials for bacterial bioterrorism agents
34. CD4+ T-cell immunity to the Burkholderia pseudomallei ABC transporter LolC in melioidosis
35. An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor
36. Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis against experimental murine Brucella melitensis infection
37. Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis for experimental murine melioidosis
38. A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection
39. Towards aBrucellavaccine for humans
40. Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection
41. Efficacy of the quinolones trovafloxacin and grepafloxacin for therapy of experimental tularaemia and plague
42. Efficacy of ciprofloxacin versus doxycycline as prophylaxis against experimental murine Brucella melitensis infection
43. Microbial TIR domains: not necessarily agents of subversion?
44. The cationic peptide magainin II is antimicrobial for Burkholderia cepacia-complex strains
45. Development and Characterization of Mouse Models of Infection with Aerosolized Brucella melitensis and Brucella suis
46. Small protective fragments of the Yersinia pestis V antigen
47. Phenotypic and Functional Characterization of Human Memory T Cell Responses to Burkholderia pseudomallei
48. Enhanced vaccine antigen delivery by Salmonella using antibiotic-free operator–repressor titration-based plasmid stabilisation compared to chromosomal integration
49. ATP-Binding Cassette Systems ofBrucella
50. Towards a human oral vaccine for anthrax: The utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.